Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Charles S. Sweet"'
Publikováno v:
Hypertension. 31:925-928
Abstract —Unexplained, persistent cough limits the use of angiotensin-converting enzyme (ACE) inhibitors in a significant number of patients. It has been speculated that occurrence of this adverse effect is genetically predetermined; in particular,
Publikováno v:
Blood Pressure. 6:35-43
The antihypertensive activity of losartan potassium (losartan, Cozaar), an angiotensin II receptor antagonist, was evaluated in a parallel 12-week, double-blind, placebo-controlled trial in hypertensive patients with mild-to-moderate hypertension. Af
Autor:
Karen E. Arcuri, D B Snavely, Edward B. Nelson, Alan H. Gradman, Allan I. Goldberg, Leila S. Ikeda, Charles S. Sweet
Publikováno v:
Hypertension. 25:1345-1350
Abstract The efficacy and safety of various doses of losartan potassium, a specific and selective angiotensin II receptor antagonist, were compared with those of placebo and enalapril maleate 20 mg in patients with mild to moderate essential hyperten
Autor:
Lukas Makris, Susan E. Keller, Charles S. Sweet, Allan I. Goldberg, Nicholas Y. Lim, Björn Dahlöf
Publikováno v:
American Journal of Hypertension. 8:578-583
The objective of this study was to compare the antihypertensive efficacy and tolerability of losartan potassium (losartan) and atenolol in patients with mild-to-moderate essential hypertension. This was a multinational, prospective, randomized, 12-we
Publikováno v:
Journal of Cardiovascular Pharmacology. 25:511-517
We examined the haemodynamic and renal response to oral losartan potassium (100 mg) during activation of the renin system in humans. Eight healthy volunteers followed a low-salt (40 mmol sodium) diet for 4 days on four occasions 2 weeks apart. Double
Publikováno v:
American Journal of Hypertension. 7:1035-1040
Losartan potassium (DuP 753), an orally active angiotensin II receptor antagonist, is metabolized to a more potent active metabolite, E-3174, which contributes to losartan's long duration of action. The acute pharmacodynamic actions of intravenous (i
Publikováno v:
Journal of Cardiovascular Pharmacology. 21:732-738
In a dose-ranging study, the angiotensin type I receptor antagonist losartan (DuP753/MK954) was administered orally to normal volunteers in whom the renin-angiotensin system (RAS) had been activated by a low sodium diet (40 mmol) and frusemide (40 mg
Autor:
Charles S. Sweet
Publikováno v:
The American Journal of Cardiology. 65:11-13
Several experimental in vitro and in vivo studies have shown that structurally diverse converting enzyme inhibitors improve contractile dysfunction, as well as reduce arrhythmia production and acute mortality after occlusion of the coronary artery. B
Autor:
Karen E. Arcuri, Jenny Toh, Roger L. Simpson, Charles S. Sweet, Allan I. Goldberg, Luis M. Ruilope
Publikováno v:
Blood pressure. 5(1)
The purpose of this trial was to evaluate the antihypertensive efficacy of the concomitant administration of selected doses of hydrochlorothiazide (HCTZ) on a background of losartan potassium (losartan) 50 mg, a selective angiotensin II receptor anta
Autor:
Allan I. Goldberg, Charles S. Sweet, Brian Wiens, Jackson T. Wright, J. Howard Pratt, Beth A. Soffer
Publikováno v:
Hypertension (Dallas, Tex. : 1979). 26(1)
Abstract The purpose of this multicenter trial was to compare the antihypertensive efficacy and safety of losartan potassium (losartan), a selective angiotensin II receptor antagonist, when added to hydrochlorothiazide in hypertensive patients whose